Financial reports
ARS
2022 FY
Annual report to shareholders
5 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
7 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Feb 24
8-K
Bankruptcy or Receivership
1 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
3 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Dec 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
30 Nov 23
8-K
Departure of Directors or Certain Officers
22 Nov 23
8-K
Termination of a Material Definitive Agreement
1 Sep 23
8-K
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury
9 Mar 23
8-K
Departure of Directors or Certain Officers
18 Nov 22
8-K
InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement
11 Oct 22
Registration and prospectus
25-NSE
Exchange delisting
21 Mar 24
424B3
Prospectus supplement
21 Nov 22
S-1
IPO registration
8 Nov 22
S-8
Registration of securities for employees
7 Nov 22
D
$6.25 mm in options / securities to be acquired, sold $6.25 mm, 1 investor
14 Oct 22
424B3
Prospectus supplement
11 Oct 22
424B5
Prospectus supplement for primary offering
11 Oct 22
S-8
Registration of securities for employees
16 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Mar 21
S-8
Registration of securities for employees
6 Nov 20
Proxies
DEF 14A
Definitive proxy
5 Dec 23
DEFA14A
Additional proxy soliciting materials
2 Sep 22
DEF 14A
Definitive proxy
18 Aug 22
PRER14A
Preliminary revised proxy
11 Aug 22
PRER14A
Preliminary revised proxy
25 Jul 22
PRE 14A
Preliminary proxy
8 Jul 22
DEFA14A
Additional proxy soliciting materials
9 Jul 21
DEFA14A
Additional proxy soliciting materials
6 Jul 21
DEFA14A
Additional proxy soliciting materials
1 Jul 21
DEF 14A
Definitive proxy
18 May 21
Other
EFFECT
Notice of effectiveness
22 Nov 22
CORRESP
Correspondence with SEC
17 Nov 22
UPLOAD
Letter from SEC
17 Nov 22
UPLOAD
Letter from SEC
19 Aug 22
CORRESP
Correspondence with SEC
18 Aug 22
UPLOAD
Letter from SEC
12 Aug 22
CORRESP
Correspondence with SEC
11 Aug 22
UPLOAD
Letter from SEC
4 Aug 22
CORRESP
Correspondence with SEC
25 Jul 22
UPLOAD
Letter from SEC
21 Jul 22
Ownership
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4/A
Brice Foose
7 Feb 24
4
Brice Foose
7 Feb 24
SC 13G/A
Foose Brice
6 Feb 24
SC 13G
Foose Brice
25 Apr 23
3
Brice Foose
24 Apr 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
Lind Global Macro Fund LP
13 Feb 23
4
RICHARD CHRISTOPHER
21 Nov 22